Quantitative determination of deferiprone in human plasma by reverse phase high performance liquid chromatography and its application to pharmacokinetic study

被引:1
作者
Abbas, Mateen [1 ,2 ]
Nawaz, Rakhshanda [2 ]
Iqbal, Tahira [2 ]
Alim, Muhammad [2 ]
Asi, Muhammad Rafique [3 ]
机构
[1] UVAS, QOL, Lahore, Pakistan
[2] Univ Agr Faisalabad, Dept Chem & Biochem, Faisalabad, Pakistan
[3] NIAB, Faisalabad, Pakistan
关键词
Deferiprone; HPLC; human; validation; pharmacokinetics; IRON CHELATOR 1,2-DIMETHYL-3-HYDROXYPYRID-4-ONE; THALASSEMIA; DESFERRIOXAMINE; L1;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Deferiprone (1, 2 dimethyl-3-hydroxypyrid-4-one) is considered to be the standard iron chelator. Pharmacokinetic studies of generic formulations are required in local condition before placed on the market. High performance liquid chromatographic (HPLC) method was used for quantification of deferiprone in human plasma using UV/VIS detector. Chromatographic separation was carried out on C-18 column, with a mobile phase of methanol-buffer (18:82, v/v), pH 3.5, and caffeine was used as an internal standard. The calibration curve was linear over the range 0.25-10 mu g/mL in human plasma (R-2 = 0.9994). After oral administration of deferiprone (500 mg) to human, the plasma concentration-time curve of deferiprone was conformed to two-compartment open model. The deferiprone plasma concentration showed a rapid absorption and average area under the plasma concentration-time curve (AUC) of deferiprone was 17.0 +/- 1.23 h.mu g/mL. Average absorption and elimination half-life values of deferiprone of 24 volunteers were 0.62 +/- 0.12 and 2.65 +/- 0.43 hours. This study confirms the rapid absorption of deferiprone in humans. AUC was similar to that previously reported but C-max was slightly lower than that stated in the literature.
引用
收藏
页码:343 / 348
页数:6
相关论文
共 20 条
[1]   PHARMACOKINETICS OF THE ORAL IRON CHELATOR DEFERIPRONE (L(1)) IN PATIENTS WITH IRON OVERLOAD [J].
ALREFAIE, FN ;
SHEPPARD, LN ;
NORTEY, P ;
WONKE, B ;
HOFFBRAND, AV .
BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (02) :403-408
[2]   Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia [J].
Anderson, LJ ;
Wonke, B ;
Prescott, E ;
Holden, S ;
Walker, JM ;
Pennell, DJ .
LANCET, 2002, 360 (9332) :516-520
[3]  
[Anonymous], 2005, ICH HARMONISED TRIPA
[4]   PROOXIDANT STATES AND TUMOR PROMOTION [J].
CERUTTI, PA .
SCIENCE, 1985, 227 (4685) :375-381
[5]   The iron chelator L1 potentiates oxidative DNA damage in iron-loaded liver cells [J].
Cragg, L ;
Hebbel, RP ;
Miller, W ;
Solovey, A ;
Selby, S ;
Enright, H .
BLOOD, 1998, 92 (02) :632-638
[6]   REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY OF NON-TRANSFERRIN-BOUND IRON AND SOME HYDROXYPYRIDONE AND HYDROXYPYRONE CHELATORS [J].
ELJAMMAL, A ;
TEMPLETON, DM .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1994, 658 (01) :121-127
[7]  
FDA Guidance for Industry, 2001, BIOAN METH VAL, P2
[8]   Beta-thalassemia [J].
Galanello, Renzo ;
Origa, Raffaella .
ORPHANET JOURNAL OF RARE DISEASES, 2010, 5
[9]  
GODDARD JG, 1990, CLIN CHEM, V36, P5
[10]   High-performance liquid chromatographic assays for a second-generation novel oral iron chelator (APCP363) and their application to pharmacokinetic studies in rats [J].
Guo, F ;
Thiessen, JJ ;
Tesoro, A ;
Spino, M .
JOURNAL OF CHROMATOGRAPHY B, 2001, 751 (01) :107-115